Stenting of saphenous vein graft (SVG) lesions is associated with a high risk of periprocedural myocardial infarction, due primarily to distal embolization. Although embolic protection devices are the only clinical trial-proven therapy for preventing periprocedural myocardial infarction during SVG interventions, they are currently used in only a small proportion of eligible patients. In this review, we present an update on the clinical data and practical recommendations for using the currently available embolic protection devices during SVG interventions.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of Invasive Cardiology|
|State||Published - Aug 1 2009|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine